Nasovac-S4 offers defence against recent surge in respiratory illnesses, say experts

New Delhi: In light of the recent surge in respiratory illnesses in China, NASOVAC-S4 emerges as a reliable defence, offering protection against influenza-induced respiratory ailments in India. This nasal vaccine is a crucial asset in protecting against respiratory infections associated with influenza in the prevailing health scenario.

The World Health Organization (WHO) has reported a rise in respiratory illnesses in the northern regions of China. The causes identified include influenza, Mycoplasma pneumonia, and SARS-CoV-2, among others.

“The recent spike in respiratory illnesses in China underscores the widespread vulnerability to infectious diseases. As the world becomes increasingly interconnected, the risk of the global transmission of respiratory pathogens is a shared concern that demands proactive measures. NASOVAC-S4 offers defence mechanism against flu”, said Dr. Neetu Jain, Pulmonologist, PSRI Hospital.

“The recent escalation in respiratory illnesses has heightened concerns about the vulnerability of our respiratory systems. From common colds to flu to more severe infections, the risk of falling ill has become a prevalent concern for individuals worldwide. This nasal vaccine, NASOVAC-S4, is specifically designed to provide a protective shield against four strains of influenza.”, said Dr. Rajiv Kapila, ENT & Head and Neck Surgeon, Deep Hospital.

NASOVAC-S4, India’s first exclusive needle-free flu vaccine, is administered through the nasal route, offering a non-invasive and painless alternative to traditional injections. It includes two influenza Type A virus strains (A/H1N1 and A/H3N2) and two influenza Type B virus strains (Victoria and Yamagata lineage). It’s efficacy and ease of administration make it an attractive option for corporate flu vaccination drives.